» Articles » PMID: 36504888

In Vivo Growth of Subclones Derived from Lewis Lung Carcinoma is Determined by the Tumor Microenvironment

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2022 Dec 12
PMID 36504888
Authors
Affiliations
Soon will be listed here.
Abstract

Heterogeneity is a fundamental feature of human tumors and plays a major role in drug resistance and disease progression. In the present study, we selected single-cell-derived cell lines (SCDCLs) derived from Lewis lung carcinoma (LLC1) cells to investigate tumorigenesis and heterogeneity. SCDCLs were generated using limiting dilution. Five SCDCLs were subcutaneously injected into wild-type C57BL/6N mice; however, they displayed significant differences in tumor growth. Subclone SCC1 grew the fastest in vivo, whereas it grew slower in vitro. The growth pattern of SCC2 was the opposite to that of SCC1. Genetic differences in these two subclones showed marked differences in cell adhesion and proliferation. Pathway enrichment results indicate that signal transduction and immune system responses were the most significantly altered functional categories in SCC2 cells compared to those in SCC1 cells in vitro. The number and activation of CD3 and CD8 T cells and NK cells in the tumor tissue of tumor-bearing mice inoculated with SCC2 were significantly higher, whereas those of myeloid cells were significantly lower, than those in the SCC1 and LLC1 groups. Our results suggest that the in vivo growth of two subclones derived from LLC1 was determined by the tumor microenvironment rather than their intrinsic proliferative cell characteristics.

Citing Articles

Pulmonary lysyl oxidase expression and its role in seeding Lewis lung carcinoma cells.

Jasmer K, Shanbhag V, Munoz Forti K, Woods L, Gudekar N, Weisman G Clin Exp Metastasis. 2024; 42(1):7.

PMID: 39714512 DOI: 10.1007/s10585-024-10325-y.


T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.

Cho N, Guldberg S, Nabet B, Yu J, Kim E, Hiam-Galvez K Cancer Immunol Res. 2024; 13(2):229-244.

PMID: 39404741 PMC: 11790381. DOI: 10.1158/2326-6066.CIR-24-0416.


MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1.

Boreel D, Sandker G, Ansems M, van den Bijgaart R, Peters J, Span P Mol Imaging Biol. 2024; 26(5):835-846.

PMID: 39009951 PMC: 11436446. DOI: 10.1007/s11307-024-01934-w.


Dynamic Changes in the Immune Microenvironment in Tumor-Draining Lymph Nodes of a Lewis Lung Cancer Mouse Model After Microwave Ablation.

Sang J, Liu P, Wang M, Xu F, Ma J, Wei Z J Inflamm Res. 2024; 17:4175-4186.

PMID: 38979433 PMC: 11228081. DOI: 10.2147/JIR.S462650.


Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids.

Zhang Y, Zhang C, Chen G, You H, Wang S, Wang X Transl Oncol. 2024; 46:102031.

PMID: 38861853 PMC: 11209639. DOI: 10.1016/j.tranon.2024.102031.


References
1.
Demmers L, Kretzschmar K, Van Hoeck A, Bar-Epraim Y, van den Toorn H, Koomen M . Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat Commun. 2020; 11(1):5338. PMC: 7577990. DOI: 10.1038/s41467-020-19142-9. View

2.
Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T . Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. J Thorac Oncol. 2021; 16(12):2078-2090. DOI: 10.1016/j.jtho.2021.07.027. View

3.
Raso M, Bota-Rabassedas N, Wistuba I . Pathology and Classification of SCLC. Cancers (Basel). 2021; 13(4). PMC: 7919820. DOI: 10.3390/cancers13040820. View

4.
To K, Fong W, Cho W . Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol. 2021; 11:635007. PMC: 8185359. DOI: 10.3389/fonc.2021.635007. View

5.
Niehr F, Eder T, Pilz T, Konschak R, Treue D, Klauschen F . Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection. Clin Cancer Res. 2017; 24(1):158-168. DOI: 10.1158/1078-0432.CCR-17-2410. View